Dasatinib + Quercetin
Quarterly pulse-dosed prescription combination. Promising mechanism, thin human evidence, real side-effect profile.
Approved Verified 27 August 2026
What it does
A senolytic combination with a promising mechanism, thin human evidence, and a real side-effect profile. The trial protocol used specific doses under medical supervision — off-the-shelf supplement quercetin is not the same thing.
Senescent cells resist apoptosis and secrete pro-inflammatory factors (the SASP). Dasatinib, a tyrosine kinase inhibitor, combined with the flavonoid quercetin, preferentially triggers apoptosis in these cells while sparing healthy ones — in theory.
What the evidence shows
Overall evidence strength: Low certainty
Who it's for, who should skip
Experimental, physician-supervised only. Components are approved (dasatinib as an oncology Rx; quercetin as a supplement), but the senolytic protocol itself is off-label, investigational use. Pulse dosing is mechanism-driven, not outcome-validated.
Running it
- Form
- oral
- Dose
- intermittent quarterly pulse
- Cycling
- pulse dosing a few days per quarter (research protocols vary); mechanism-driven, not outcome-validated
Safety
- dasatinib carries a real tyrosine-kinase-inhibitor side-effect profile; pulse dosing limits but does not eliminate exposure
Stacking & alternatives
Access & cost
Prescription or clinician order — typically via physician (off-label senolytic protocol).
Last reviewed 27 August 2026. Regulatory status verified 27 August 2026.